Peptide · Fact sheet
Liraglutide
Also known as Victoza · Saxenda
Liraglutide is FDA approved in products for type 2 diabetes and chronic weight management. Approval and age criteria depend on the exact product label.
What is Liraglutide?
Liraglutide is a manufactured GLP-1 analog. It acts on a receptor involved in blood-sugar regulation, appetite, and digestion.
Victoza and Saxenda contain liraglutide but have different labeled uses and should not be treated as a single generic claim.
Benefits & claims
Liraglutide has a longer clinical history than several other incretin medicines.
Readers often compare its evidence, schedule, outcomes, and risks with semaglutide and tirzepatide.
What the evidence supports
- Controlled trials support benefits for blood-sugar control and chronic weight management in labeled populations.
- The amount and type of benefit differ by population, endpoint, and product indication.
Research areas
- Type 2 diabetes
- Chronic weight management
- Cardiovascular outcomes
- Other metabolic outcomes outside current labels
Dosage & frequency
Product-specific label informationVictoza and Saxenda contain liraglutide but have different labeled uses and maintenance amounts. Both are daily medicines.
Victoza
Adults and patients age ten years and older with type 2 diabetes
- Amount
- 0.6 mg initially; 1.2 mg after at least one week; up to 1.8 mg if needed
- Frequency
- Once daily
- Route studied or labeled
- Subcutaneous
Adult 0.6 mg is an initiation amount, not an effective glycemic maintenance amount.
Saxenda
Adults meeting labeled weight-management criteria
- Amount
- Start 0.6 mg; weekly 0.6 mg increments to 3 mg maintenance
- Frequency
- Once daily
- Route studied or labeled
- Subcutaneous
Weight-management product; titration and stopping rules are product-specific.
Saxenda: pediatric
Patients age twelve years and older, above 60 kg, meeting labeled obesity criteria
- Amount
- 3 mg maintenance; 2.4 mg if 3 mg is not tolerated
- Frequency
- Once daily
- Route studied or labeled
- Subcutaneous
Pediatric titration and tolerability provisions differ from adult use.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Victoza is the diabetes product; Saxenda is the weight-management product.
Interactions & precautions
- Insulin or insulin secretagogues can increase hypoglycemia risk; gastric emptying can affect oral medicines.
What is still unresolved
- Results in obesity or diabetes do not establish a general longevity indication.
Side effects & risks
- Gastrointestinal effects such as nausea, diarrhea, constipation, and vomiting are common.
- Labels include a boxed warning related to thyroid C-cell tumors in rodents and list important contraindications.
- Other concerns can include pancreatitis, gallbladder disease, kidney problems related to dehydration, and low blood sugar with certain other medicines.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesLarge clinical programs support approved uses, including cardiovascular outcomes evidence in a labeled diabetes population.
Studies
Registry record for the liraglutide cardiovascular outcomes trial.
Peer-reviewed report of a large liraglutide cardiovascular outcomes trial.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| LEADER Type 2 diabetes and high cardiovascular risk 9,340 participants (actual) Randomized placebo-controlled trial; human | Liraglutide versus Placebo Median follow-up 3.8 years Primary: First cardiovascular death, nonfatal heart attack or nonfatal stroke Phase: Not listed in this summary | 608/4668 (13.0%) versus 694/4672 (14.9%) had a primary event. 1.9 percentage points fewer events, using rounded published proportions. Hazard ratio 0.87; 95% CI 0.78–0.97. Cannot tell us: Population differs from SELECT; these two placebo comparisons cannot rank liraglutide against semaglutide. Safety, uncertainty, and source detailsGastrointestinal events most commonly led to discontinuation. Limited to the studied population, formulation and follow-up. Funding/conflicts: Novo Nordisk and NIH; individual disclosures not fully extracted. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
Who was studied in LEADER?
Reduced composite cardiovascular events in adults with type 2 diabetes and high cardiovascular risk.
Limit: The trial does not answer the same population question as SELECT.
Check the sources: LEADER: liraglutide cardiovascular outcomes (checked 2026-09-18) · FDA Victoza prescribing information (checked 2026-09-18)
What is approved, and for whom?
United States records selected for the questions above; not a complete label or a worldwide approval inventory.
Victoza: Cardiovascular outcomes
Subcutaneous injection · Adults with type 2 diabetes and established cardiovascular disease
approved — Does not transfer to people without diabetes or establish general longevity benefit.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18
Compare research questions · Submit a source-based correction
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Appetite: reported experiences
Fewer food thoughts and weight loss
A person with PCOS described weight loss over three months and fewer uncontrollable cravings during Saxenda treatment, alongside walking and dietary changes. Marked thirst early on reportedly passed.
Reported use in this account
- Product
- Saxenda; the source does not state an amount unit
- Amount
- Not specified clearly
- Frequency
- Every day
- Route
- Injection; specific route not stated
- Duration
- About three months
Other exposures described: Walking and dietary changes; Other PCOS treatments; details not stated; Earlier mental-health medicines and an injectable contraceptive
The source omits an amount unit, so no mass amount is assigned. Weight and diagnosis were self-reported; other PCOS treatments, earlier medicine changes, diet and activity limit attribution.
Read the original accountSubstantial loss with constipation
A 57-year-old woman described weight loss over six months, earlier fullness and constipation while also tracking a calorie deficit.
Reported use in this account
- Product
- Product described as liraglutide
- Amount
- Not specified clearly
- Frequency
- Every morning
- Route
- Not specified clearly
- Duration
- 24 weeks, described as six months
Other exposures described: Calorie tracking; Occasional polyethylene glycol and magnesium oxide
The weight change is self-reported and accompanied dietary changes. This is not an estimate of expected loss.
Read the original accountWeight: reported experiences
Fewer food thoughts and weight loss
A person with PCOS described weight loss over three months and fewer uncontrollable cravings during Saxenda treatment, alongside walking and dietary changes. Marked thirst early on reportedly passed.
Reported use in this account
- Product
- Saxenda; the source does not state an amount unit
- Amount
- Not specified clearly
- Frequency
- Every day
- Route
- Injection; specific route not stated
- Duration
- About three months
Other exposures described: Walking and dietary changes; Other PCOS treatments; details not stated; Earlier mental-health medicines and an injectable contraceptive
The source omits an amount unit, so no mass amount is assigned. Weight and diagnosis were self-reported; other PCOS treatments, earlier medicine changes, diet and activity limit attribution.
Read the original accountLittle early loss and slower digestion
A commenter described only a small weight change after about three weeks and noticeably slower bowel activity.
Reported use in this account
- Product
- Product described as liraglutide
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About three weeks
The short account lacks baseline measurements and other-treatment details; it cannot predict longer-term response.
Read the original accountSubstantial loss with constipation
A 57-year-old woman described weight loss over six months, earlier fullness and constipation while also tracking a calorie deficit.
Reported use in this account
- Product
- Product described as liraglutide
- Amount
- Not specified clearly
- Frequency
- Every morning
- Route
- Not specified clearly
- Duration
- 24 weeks, described as six months
Other exposures described: Calorie tracking; Occasional polyethylene glycol and magnesium oxide
The weight change is self-reported and accompanied dietary changes. This is not an estimate of expected loss.
Read the original accountDigestion: reported experiences
Little early loss and slower digestion
A commenter described only a small weight change after about three weeks and noticeably slower bowel activity.
Reported use in this account
- Product
- Product described as liraglutide
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- About three weeks
The short account lacks baseline measurements and other-treatment details; it cannot predict longer-term response.
Read the original accountSubstantial loss with constipation
A 57-year-old woman described weight loss over six months, earlier fullness and constipation while also tracking a calorie deficit.
Reported use in this account
- Product
- Product described as liraglutide
- Amount
- Not specified clearly
- Frequency
- Every morning
- Route
- Not specified clearly
- Duration
- 24 weeks, described as six months
Other exposures described: Calorie tracking; Occasional polyethylene glycol and magnesium oxide
The weight change is self-reported and accompanied dietary changes. This is not an estimate of expected loss.
Read the original accountApproval status
FDA-approved liraglutide products have indications for type 2 diabetes or chronic weight management in defined populations. Check current labeling for age and eligibility details.
Approved uses
- Improving blood sugar control in specified people with type 2 diabetes
- Chronic weight management in specified adults and adolescents
- Reducing specified cardiovascular risks under the applicable label
FDA approved for labeled products
FDA labels cover liraglutide products for specific diabetes and chronic-weight-management uses. The exact indication, age range, and risk language depend on the product.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- How outcomes compare directly across related medicines and populations
- Whether research outside approved uses will produce meaningful clinical benefits
- Individual benefit-risk tradeoffs that require a clinician's review
Summary
Liraglutide’s evidence and approval depend on the exact product, population and use.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA prescribing information: Victoza
Official prescribing information for a liraglutide type 2 diabetes product.
- clinical trialsClinicalTrials.gov: LEADER cardiovascular outcomes trial
Registry record for the liraglutide cardiovascular outcomes trial.
- pubmedLEADER liraglutide cardiovascular outcomes trial
Peer-reviewed report of a large liraglutide cardiovascular outcomes trial.